Brain Health Nexus
As a nonprofit biomedical and technology research organization dedicated to advancing brain health, we recognize that the health consequences of the pandemic have normalized an understanding of global stress and trauma, escalating the urgency to galvanize individuals and institutions in the brain health ecosystem towards a shared mission. We know that now is the time to ensure brain health moves to the top of national and global agendas, with a clear plan for how resources will be deployed.
Over the past five years CVB has laid the foundation for designing roadmaps for collective action, with innovative research to fast-track solutions for complex diseases, the development of tools and platforms that cut across brain health, and an advocacy agenda to drive brain health precision medicine. But we recognize that meaningful change across brain health will require a global collective movement that pools resources and expertise and incorporates diverse, driven leadership. CVB is eager to catalyze this movement by joining forces with others to work towards a shared vision and purpose to move from ideation to action.
Transformation at the intersection of information, science & technology.
Moore’s Law for Medicine.
The 1990s witnessed an important and dynamic evolution in the global semiconductor industry, driven by marked technological innovations, a newly aggressive U.S. R&D Strategy and a global dispersion of the production infrastructure for the industry. Together, these major forces transformed the world technically, economically and socially.
Progress in semiconductor R&D was not incremental, nor was it organic, it was forged by the adoption of two principles – Moore’s Law and Radical Investment in Roadmaps.
The former predicted the pace of innovation that was feasible, the latter foster open discussion of industry-wide R&D needs and explicit coordination of efforts across companies.
Critically, these roadmaps focused on “failure mode analysis” and solutions generation based on clearly defined milestones.
The advancement of precision therapeutics for brain health depends on a robust & reliable translational research infrastructure. Innovative technologies and solutions are stalled due to well-known challenges in our research enterprise.
Each of these, in turn, are hampered by specific ‘failure-modes’ that could be addressed through top- down designed, multi-sector Action Plans. A failure mode and effects analysis (FMEA) is a step-by-step approach for identifying all possible failures in a design, a process (e.g. manufacturing or assembly), or a product or service. It is a common process analysis tool.
To address these challenges – we need a Roadmap.
The Scientific & Technology Roadmap will be a collaborative data-driven effort to address the relationship of R&D challenges to specific failure-modes (e.g. lack of an available assay, platform or standard) and the generation of specifications to be met in solutions-generation.